Insider Selling: Guardant Health (NASDAQ:GH) Insider Sells 3,832 Shares of Stock

Key Points

• Insider sale: Terilyn Monroe sold 3,832 Guardant Health shares on April 6 under a pre-arranged Rule 10b5-1 plan at an average price of $92.68, totaling $355,149.76 and reducing her holding by 15.44% to 20,990 shares (≈$1.945M).
• Shares traded up about 4.1% to $93.30 on higher-than-average volume; the company recently reported revenue up 39.4% (beat) but missed EPS at ($0.50) versus ($0.43), and the stock carries a consensus Moderate Buy rating with an average target of $125.95.
• Institutional ownership is high at 92.6%, with major funds (notably Invesco and AQR) increasing positions in recent quarters, signaling strong institutional interest.

Guardant Health, Inc. (NASDAQ:GH - Get Free Report) insider Terilyn Monroe sold 3,832 shares of the stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $92.68, for a total transaction of $355,149.76. Following the completion of the transaction, the insider owned 20,990 shares in the company, valued at $1,945,353.20. This represents a 15.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Guardant Health Stock Up 4.1%

Guardant Health stock traded up $3.64 during mid-day trading on Tuesday, hitting $93.30. The company had a trading volume of 2,248,053 shares, compared to its average volume of 2,000,690. The stock has a market cap of $12.24 billion, a price-to-earnings ratio of -28.19 and a beta of 1.64. Guardant Health, Inc. has a 1 year low of $36.36 and a 1 year high of $120.74. The business has a fifty day moving average of $96.57 and a 200 day moving average of $93.16.

Guardant Health (NASDAQ:GH - Get Free Report) last announced its quarterly earnings results on Thursday, February 19th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The business had revenue of $281.27 million for the quarter, compared to the consensus estimate of $269.74 million. The firm's revenue was up 39.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.62) EPS. Equities analysts anticipate that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Institutional Investors Weigh In On Guardant Health

Several hedge funds have recently modified their holdings of GH. AQR Capital Management LLC lifted its holdings in shares of Guardant Health by 56.5% during the first quarter. AQR Capital Management LLC now owns 71,534 shares of the company's stock worth $3,012,000 after purchasing an additional 25,831 shares during the period. Empowered Funds LLC acquired a new stake in shares of Guardant Health during the first quarter worth $274,000. Invesco Ltd. lifted its holdings in Guardant Health by 27.3% in the second quarter. Invesco Ltd. now owns 3,558,501 shares of the company's stock valued at $185,184,000 after acquiring an additional 763,834 shares during the period. Guggenheim Capital LLC lifted its holdings in Guardant Health by 2.5% in the second quarter. Guggenheim Capital LLC now owns 87,270 shares of the company's stock valued at $4,542,000 after acquiring an additional 2,111 shares during the period. Finally, Bosun Asset Management LLC acquired a new stake in Guardant Health in the second quarter valued at $328,000. 92.60% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. UBS Group restated a "buy" rating and set a $175.00 target price on shares of Guardant Health in a research report on Friday, January 30th. Citigroup raised their target price on shares of Guardant Health from $135.00 to $150.00 and gave the stock a "buy" rating in a research report on Friday, February 20th. Stifel Nicolaus raised their target price on shares of Guardant Health from $120.00 to $130.00 and gave the stock a "buy" rating in a research report on Friday, February 20th. Canaccord Genuity Group raised their target price on shares of Guardant Health from $125.00 to $135.00 and gave the stock a "buy" rating in a research report on Friday, February 20th. Finally, Piper Sandler raised their target price on shares of Guardant Health from $120.00 to $130.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 24th. Twenty equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $125.95.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health's mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company's flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.